Locoregional therapies for metastatic colorectal carcinoma to the liver - An evidence-based review

Journal of Surgical Oncology

Volumn 110, Issue 2, 2014, Pages 182-196

  Xing, Minzhi ^a,b   Kooby, David A ^b   El Rayes, Bassel F ^b   Kokabi, Nima ^b   Camacho, Juan C ^b   Kim, Hyun S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; YTTRIUM 90;

ABDOMINAL PAIN; ABSCESS; ASCITES; ASTHENIA; BILIARY SCLEROSIS; BILIARY TRACT DISEASE; BILOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; DIGESTIVE SYSTEM ULCER; DRUG ELUTING BEAD TRANSARTERIAL CHEMOTHERAPY EMBOLIZATION; FEVER; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATITIS; HUMAN; LOCAL THERAPY; OVERALL SURVIVAL; PANCREATITIS; PATIENT SAFETY; PEPTIC ULCER; PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOEMBOLIZATION; REVIEW; SALVAGE THERAPY; SYSTEMIC THERAPY; THERAPY EFFECT; VOMITING;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

EID: 84903980580     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23619     Document Type: Review

References (125)

1. Jemal A, Bray F, Center MM, et al.: Global cancer statistics. Cancer 2011; 61: 69-90.
2. Seo SI, Lim SB, Yoon YS, et al.: Comparison of recurrence patterns between ≤5 Years and>5 years after curative operations in colorectal cancer patients. J Surg Oncol 2013; 108: 9-13.
3. Van Cutsem E, Nordlinger B, Adam R, et al.: Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221. (Pubitemid 44307626)
4. Kemeny N, Kemeny M, Lawrence T,: Liver metastases. In:, Abeloff M, Armitage J, Niederhuber J, Lichter A, editors. Clinical oncology, 3rd edition. Philadelphia, PA: Elsevier Clinical Oncology; 2004. pp. 1141-1178.
5. Poston GJ,: Surgical strategies for colorectal liver metastases. Surg Oncol 2004; 13: 125-136. (Pubitemid 39572086)
6. Wei AC, Greig PD, Grant D, et al.: Survival after hepatic resection for colorectal metastases: A 10-year experience. Ann Surg Oncol 2006; 13: 668-676.
7. Abdalla EK, Adam R, Bilchik AJ, et al.: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280. (Pubitemid 44435793)
8. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-766. (Pubitemid 34547293)
9. Gallagher DJ, Kemeny N,: Metastatic colorectal cancer: From improved survival to potential cure. Oncology 2010; 78: 237-248.
10. Scheele J, Stang R, Altendorf-Hofmann A, et al.: Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
11. Gayowski TJ, Iwatsuki S, Madariaga JR, et al.: Experience in hepatic resection for metastatic colorectal cancer: Analysis of clinical and pathologic risk factors. Surgery 1994; 116: 703-710, discussion 710-711.
12. Ekberg H, Tranberg KG, Andersson R, et al.: Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73: 727-731. (Pubitemid 16011176)
13. Charnsangavej C, Clary B, Fong Y, et al.: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1261-1268. (Pubitemid 44435791)
14. Gallagher DJ, Zheng J, Capanu M, et al.: Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases. Ann Surg Oncol 2009; 16: 1844-1851.
15. Elias D, Ouellet JF, Bellon N, et al.: Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg 2003; 90: 567-574. (Pubitemid 36577888)
16. Geoghegan JG, Scheele J,: Treatment of colorectal liver metastases. Br J Surg 1999; 86: 158-169. (Pubitemid 29090178)
17. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371: 1007-1016. (Pubitemid 351392040)
18. Nordlinger B, Van Cutsem E, Rougier P, et al.: Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045. (Pubitemid 47380368)
19. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240: 644-657, discussion 657-658.
20. Cosimelli M, Golfieri R, Cagol PP, et al.: Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 2010; 103: 324-331.
21. Mahnken AH, Pereira PL, de Baere T,: Interventional oncologic approaches to liver metastases. Radiology 2013; 266: 407-430.
22. Lucke B, Breedis C, Woo ZP, et al.: Differential growth of blood-borne metastatic tumors in liver and lung (experiments with rabbit V-2 carcinoma). Am J Pathol 1951; 27: 729-730.
23. Ackerman NB,: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974; 75: 589-596.
24. Ensminger WD, Gyves JW,: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 1983; 10: 176-182. (Pubitemid 13050371)
25. Sigurdson ER, Ridge JA, Kemeny N, et al.: Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987; 5: 1836-1840. (Pubitemid 18020851)
26. Stagg RJ, Venook AP, Chase JL, et al.: Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83: 423-428.
27. Kerr DJ, McArdle CS, Ledermann J, et al.: Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: A multicentre randomised trial. Lancet 2003; 361: 368-373. (Pubitemid 36164968)
28. Ducreux M, Ychou M, Laplanche A, et al.: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: A trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881-4887. (Pubitemid 46223993)
29. Boige V, Malka D, Elias D, et al.: Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15: 219-226.
30. Sharma RA, Van Hazel GA, Morgan B, et al.: Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106. (Pubitemid 46596762)
31. Kemeny NE, Niedzwiecki D, Hollis DR, et al.: Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403. (Pubitemid 46622004)
32. Kemeny NE, Melendez FDH, Capanu M, et al.: Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2009; 27: 3465-3471.
33. Malka D, Paris E, Caramella C,: Combined hepatic oxaliplatin, intravenous LV5FU2 and Erbitux. Proc ASCO 2010 abstr. 2010; 3558.
34. Louvet C, de Gramont A, Tournigand C, et al.: Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001; 91: 2033-2038. (Pubitemid 32479191)
35. Sidhu R, Rong A, Dahlberg S,: Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clin Cancer Res 2013; 19: 969-976.
36. Chang AE, Schneider PD, Sugarbaker PH, et al.: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206: 685-693. (Pubitemid 18056182)
37. Kemeny N, Daly J, Reichman B, et al.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107: 459-465. (Pubitemid 17149758)
38. Hohn DC, Stagg RJ, Friedman MA, et al.: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern California Oncology Group trial. J Clin Oncol 1989; 7: 1646-1654. (Pubitemid 19272834)
39. Wagman LD, Kemeny MM, Leong L, et al.: A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990; 8: 1885-1893. (Pubitemid 20382353)
40. Martin JK, Jr., O'Connell MJ, Wieand HS, et al.: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125: 1022-1027. (Pubitemid 20249340)
41. Lorenz M, Muller HH,: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000; 18: 243-254. (Pubitemid 30056411)
42. Mocellin S, Pilati P, Lise M, et al.: Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era ? J Clin Oncol 2007; 25: 5649-5654.
43. Rougier P, Laplanche A, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial. J Clin Oncol 1992; 10: 1112-1118.
44. Allen-Mersh TG, Earlam S, Fordy C, et al.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994; 344: 1255-1260. (Pubitemid 24334681)
45. van Riel JM, van Groeningen CJ, de Greve J, et al.: Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004; 15: 59-63.
46. van Riel JMGH, van Groeningen CJ, Kedde MA, et al.: Continuous administration of irinotecan by hepatic arterial infusion: A phase I and pharmacokinetic study. Clin Cancer Res 2002; 8: 405-412. (Pubitemid 34193957)
47. Dzodic R, Gomez-Abuin G, Rougier P, et al.: Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin administration: Comparative results with cisplatin using a rabbit VX2 tumor model. Anticancer Drugs 2004; 15: 647-650. (Pubitemid 38932336)
48. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048. (Pubitemid 30035952)
49. Mocellin S, Pasquali S, Nitti D,: Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009; CD007823.
50. Kemeny N, Capanu M, D'Angelica M, et al.: Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1236-1241.
51. Nelson R, Freels S,: Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev 2006; CD003770.
52. Alberts SR, Roh MS, Mahoney MR, et al.: Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: A North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol 2010; 28: 853-858.
53. Elias D, Goere D, Boige V, et al.: Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: Impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194. (Pubitemid 47594272)
54. de Baere T, Deschamps F,: Arterial therapies of colorectal cancer metastases to the liver. Abdom Imaging 2011; 36: 661-670.
55. Deschamps F, Rao P, Teriitehau C, et al.: Percutaneous femoral implantation of an arterial port catheter for intraarterial chemotherapy: Feasibility and predictive factors of long-term functionality. J Vasc Interv Radiol 2010; 21: 1681-1688.
56. Barnett KT, Malafa MP,: Complications of hepatic artery infusion: A review of 4580 reported cases. Int J Gastrointest Cancer 2001; 30: 147-160. (Pubitemid 36306730)
57. Kemeny MM, Battifora H, Blayney DW, et al.: Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202: 176-181. (Pubitemid 15041717)
58. Kemeny N, Seiter K, Niedzwiecki D, et al.: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992; 69: 327-334.
59. Abdalla EK, Bauer TW, Chun YS, et al.: Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: Expert consensus statements. HPB (Oxford) 2013; 15: 119-130.
60. Ensminger WD,: Intrahepatic arterial infusion of chemotherapy: Pharmacologic principles. Semin Oncol 2002; 29: 119-125. (Pubitemid 34297282)
61. Allen PJ, Nissan A, Picon AI, et al.: Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: An institutional experience of 544 consecutive cases. J Am Coll Surg 2005; 201: 57-65. (Pubitemid 40840564)
62. Tajima T, Yoshimitsu K, Kuroiwa T, et al.: Percutaneous femoral catheter placement for long-term chemotherapy infusions: Preliminary technical results. Am J Roentgenol 2005; 184: 906-914. (Pubitemid 43899520)
63. Tanaka T, Arai Y, Inaba Y, et al.: Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy. J Vasc Interv Radiol 2003; 14: 63-68. (Pubitemid 36134075)
64. Deschamps F, Elias D, Goere D, et al.: Intra-arterial hepatic chemotherapy: A comparison of percutaneous versus surgical implantation of port-catheters. Cardiovasc Intervent Radiol 2011; 34: 973-979.
65. Aldrighetti L, Arru M, Angeli E, et al.: Percutaneous vs. surgical placement of hepatic artery indwelling catheters for regional chemotherapy. Hepatogastroenterology 2002; 49: 513-517. (Pubitemid 34606585)
66. Solomon B, Soulen MC, Baum RA, et al.: Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: Prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10: 793-798. (Pubitemid 29284310)
67. Memon K, Lewandowski RJ, Riaz A, et al.: Chemoembolization and radioembolization for metastatic disease to the liver: Available data and future studies. Curr Treat Options in Oncol 2012; 13: 403-415.
68. Soulen MC,: Chemoembolization of hepatic malignancies. Oncology (Williston Park) 1994; 8: 77-84, discussion, 89-90 passim. (Pubitemid 24140439)
69. Lang EK, Brown CL,: Colorectal metastases to the liver: Selective chemoembolization. Radiology 1993; 189: 417-422. (Pubitemid 23321421)
70. Martinelli DJ, Wadler S, Bakal CW, et al.: Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994; 74: 1706-1712. (Pubitemid 24301823)
71. Vogl TJ, Gruber T, Balzer JO, et al.: Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: Prospective study. Radiology 2009; 250: 281-289.
72. Pohlen U, Mansmann U, Berger G, et al.: Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases. Anticancer Res 2004; 24: 3275-3282. (Pubitemid 39390985)
73. Albert M, Kiefer MV, Sun W, et al.: Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer 2011; 117: 343-352.
74. Leichman CG, Jacobson JR, Modiano M, et al.: Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial. Cancer 1999; 86: 775-781. (Pubitemid 29399916)
75. Muller H, Nakchbandi V, Chatzisavvidis I, et al.: Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepatogastroenterology 2003; 50: 1919-1926. (Pubitemid 37467962)
76. Yu J-S, Kim KW, Jeong M-G, et al.: Predisposing factors of bile duct injury after transcatheter arterial chemoembolization (TACE) for hepatic malignancy. Cardiovasc Intervent Radiol 2002; 25: 270-274. (Pubitemid 36919621)
77. Kim HK, Chung YH, Song BC, et al.: Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 2001; 32: 423-427. (Pubitemid 32378276)
78. Chung JW, Park JH, Han JK, et al.: Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: 33-40.
79. Xia J, Ren Z, Ye S, et al.: Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. Eur J Radiol 2006; 59: 407-412. (Pubitemid 44314072)
80. Lewandowski RJ, Thurston KG, Goin JE,: 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: Response to treatment at targeted doses of 135-150 Gy as measured by [18F] fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 2005; 16: 1641-1651. (Pubitemid 44431161)
81. Prajapati HJ, Dhanasekaran R, El-Rayes BF, et al.: Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24: 307-315.
82. Bower M, Metzger T, Robbins K, et al.: Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: A multi-institutional study. HPB (Oxford) 2010; 12: 31-36.
83. Martin RC, II, Scoggins CR, Tomalty D, et al.: Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: Results of pharmacokinetics and phase I trial. J Gastrointest Surg 2012; 16: 1531-1538.
84. Fiorentini G, Aliberti C, Tilli M, et al.: Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: Final results of a phase III study. Anticancer Res 2012; 32: 1387-1395.
85. Martin RC, Joshi J, Robbins K, et al.: Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: Results of multi-institutional study. Ann Surg Oncol 2011; 18: 192-198.
86. Fiorentini G, Aliberti C, G.B. Del Conte A, et al.: Evaluation at 16 months of a phase III study comparing TACE-DC beads IRI loaded (DEBIRI) with FOLFIRI (CT) for patients with nonre- sectable colorectal cancer (CRC) liver metastases (LM). Proc ASCO 2009 abstr. 2009; 4092.
87. Hong K, McBride JD, Georgiades CS, et al.: Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: Comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20: 360-367.
88. Fiorentini G, Aliberti C, Benea G, et al.: TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: Beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepatogastroenterology 2008; 55: 2077-2082.
89. Martin RC, Howard J, Tomalty D, et al.: Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: Results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33: 960-966.
90. Vogl TJ, Lammer J, Lencioni R, et al.: Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: Results from the PRECISION V randomized trial. Am J Roentgenol 2011; 197: W562-W570.
91. Emami B, Lyman J, Brown A, et al.: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21: 109-122.
92. Russell AH, Clyde C, Wasserman TH, et al.: Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: Results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993; 27: 117-123. (Pubitemid 23270664)
93. Campbell AM, Bailey IH, Burton MA,: Analysis of the distribution of intra-arterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2000; 45: 1023-1033. (Pubitemid 30196393)
94. Campbell AM, Bailey IH, Burton MA,: Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 2001; 46: 487-498. (Pubitemid 32148511)
95. Sarfaraz M, Kennedy AS, Lodge MA, et al.: Radiation absorbed dose distribution in a patient treated with yttrium-90 microspheres for hepatocellular carcinoma. Med Phys 2004; 31: 2449-2453. (Pubitemid 39287858)
96. Murthy R, Kamat P, Nunez R, et al.: Radioembolization of yttrium-90 microspheres for hepatic malignancy. Semin Intervent Radiol 2008; 25: 48-57.
97. Salem R, Thurston KG,: Radioembolization with 90yttrium microspheres: A state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. J Vasc Interv Radiol 2006; 17: 1251-1278. (Pubitemid 44259009)
98. Van den Eynde M, Flamen P, El Nakadi I, et al.: Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 2008; 33: 697-699.
99. Giammarile F, Bodei L, Chiesa C, et al.: EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011; 38: 1393-1406.
100. Kennedy A, Nag S, Salem R, et al.: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23. (Pubitemid 46589861)
101. Wong C, Salem R, Raman S, et al.: Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: A comparison with CT or MRI. Eur J Nucl Med 2002; 29: 815-820.
102. Wong C, Salem R, Qing F, et al.: Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: Comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004; 45: 1892-1897. (Pubitemid 47618448)
103. Goin J, Dancey J, Hermann G, et al.: Treatment of unresectable metastatic colorectal carcinoma to the liver with intrahepatic Y-90 microspheres: A dose-ranging study. World J Nucl Med 2003; 2: 216-225.
104. Kennedy AS, Coldwell D, Nutting C, et al.: Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65: 412-425.
105. Jakobs TF, Hoffmann R-T, Dehm K, et al.: Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008; 19: 1187-1195.
106. Van Hazel G, Blackwell A, Anderson J, et al.: Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88: 78-85. (Pubitemid 39536508)
107. Hendlisz A, Eynde MVd, Peeters M, et al.: Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694.
108. Nicolay NH, Berry DP, Sharma RA,: Liver metastases from colorectal cancer: Radioembolization with systemic therapy. Nat Rev Clin Oncol 2009; 6: 687-697.
109. Gray B, Van Hazel G, Hope M, et al.: Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001; 12: 1711-1720. (Pubitemid 34105661)
110. Vente MAD, Wondergem M, van der Tweel I, et al.: Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: A structured meta-analysis. Eur Radiol 2009; 19: 951-959.
111. Salem R, Lewandowski RJ, Kulik L, et al.: Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497.e2-507.e2.
112. Riaz A, Lewandowski RJ, Kulik LM, et al.: Complications following radioembolization with yttrium-90 microspheres: A comprehensive literature review. J Vasc Interv Radiol 2009; 20: 1121-1130, quiz 31.
113. Salem R, Lewandowski RJ, Atassi B, et al.: Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): Safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16: 1627-1639. (Pubitemid 44431160)
114. Murthy R, Xiong H, Nunez R, et al.: Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: Preliminary results. J Vasc Interv Radiol 2005; 16: 937-945. (Pubitemid 40993516)
115. Sangro B, Gil-Alzugaray B, Rodriguez J, et al.: Liver disease induced by radioembolization of liver tumors: Description and possible risk factors. Cancer 2008; 112: 1538-1546. (Pubitemid 351441166)
116. Leung TW, Lau WY, Ho SK, et al.: Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995; 33: 919-924.
117. Young JY, Rhee TK, Atassi B, et al.: Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18: 1375-1382. (Pubitemid 47628904)
118. Jakobs TF, Saleem S, Atassi B, et al.: Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci 2008; 53: 2556-2563.
119. Rhee TK, Naik NK, Deng J, et al.: Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: Comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008; 19: 1180-1186.
120. Kennedy AS, McNeillie P, Dezarn WA, et al.: Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500.
121. Sanz-Altamira PM, Spence LD, Huberman MS, et al.: Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: A phase II trial. Dis Colon Rectum 1997; 40: 770-775. (Pubitemid 27295046)
122. Voigt W, Behrmann C, Schlueter A, et al.: A new chemoembolization protocol in refractory liver metastasis of colorectal cancer-A feasibility study. Onkologie 2002; 25: 158-164. (Pubitemid 34507665)
123. Eichler K, Zangos S, Mack MG, et al.: First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol 2012; 41: 1213-1220.
124. Narayanan G, Barbery K, Suthar R, et al.: Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 2013; 33: 2077-2083.
125. Tellez C, Benson AB 3rd, Lyster MT, Talamonti M, Shaw J, Braun MA, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 1998; 82: 1250-1259. (Pubitemid 28155386)